Analysts Issue “Hold” Rating for LivaNova PLC Stock
July 26, 2023
🌥️Trending News
LIVANOVA ($NASDAQ:LIVN): LivaNova PLC is a leading medical technology company that provides innovative therapies to improve patients’ lives around the world. Recently, five different ratings firms conducted studies on the company’s stock and have assigned it a consensus rating of “Hold.” Analysts believe that while the stock is unlikely to fall in value, its current price does not present a compelling enough reason to buy. They cite potential risks and lack of growth as reasons for their rating. The stock remains a safe option for those looking to diversify their portfolios without taking on too much risk.
Moreover, analysts believe that there is still potential for growth in the stock in the long term. Regardless of the current “Hold” rating, investors should always do their own research before making any decisions about investing in LivaNova PLC. By understanding the company’s financials, potential risks, and growth opportunities, investors can make an informed decision about whether or not to invest in the stock.
Stock Price
Analysts recently issued a “Hold” rating for LivaNova PLC stock. On Monday, the stock opened at $53.1 and closed at $52.9, a 0.5% decrease from the previous day’s closing price of $53.2. Though the stock dipped slightly, analysts are still recommending investors to hold their shares due to the potential for future growth.
Analysts remain optimistic that this medical technology company will continue to develop its products and expand its reach in order to bring innovation and improve patient care. As a result, they believe that LivaNova PLC stock will be a good long-term investment. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Livanova Plc. More…
| Total Revenues | Net Income | Net Margin |
| 1.05k | -81.84 | -4.2% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Livanova Plc. More…
| Operations | Investing | Financing |
| 64.9 | -44.43 | 60.05 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Livanova Plc. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 2.29k | 1.07k | 22.55 |
Key Ratios Snapshot
Some of the financial key ratios for Livanova Plc are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| -1.0% | -15.9% | -1.6% |
| FCF Margin | ROE | ROA |
| 3.4% | -0.9% | -0.5% |
Analysis
GoodWhale has conducted an in-depth analysis of LIVANOVA PLC‘s financials. After carefully evaluating the financial and business aspects of this investment, we have determined that it is a high risk investment. Two significant risk warnings were observed in the income sheet and balance sheet of LIVANOVA PLC. In order to gain a better understanding of the potential risks associated with this investment, we recommend that you register with us to view our detailed analysis. With GoodWhale, you can be sure to make informed decisions when it comes to your investments. More…
Peers
The company’s products include implantable cardioverter defibrillators, pacemakers, percutaneous transluminal coronary angioplasty catheters, stents, and thrombectomy devices. LivaNova PLC operates in Europe, the United States, Asia Pacific, the Middle East, and Africa. The company was formerly known as Sorin Group S.p.A. and changed its name to LivaNova PLC in February 2016. LivaNova PLC was founded in 1956 and is headquartered in London, the United Kingdom. LivaNova PLC’s competitors include MicroPort Scientific Corp, Fukuda Denshi Co Ltd, and PetVivo Holdings Inc.
– MicroPort Scientific Corp ($SEHK:00853)
MicroPort Scientific Corp is a medical device company that develops, manufactures, and markets a broad range of products and solutions for the treatment of cardiovascular diseases. The company has a market cap of 31.83B as of 2022 and a return on equity of -19.11%. MicroPort’s products and solutions are used in a variety of procedures, including coronary angioplasty, stenting, and valve replacement. The company’s products are sold in over 50 countries worldwide.
– Fukuda Denshi Co Ltd ($TSE:6960)
With a market cap of 114.93B as of 2022, Fukuda Denshi Co Ltd is one of the largest companies in Japan. The company produces a wide range of products, including medical equipment, electronic products, and communications equipment. The company has a strong reputation for quality and innovation, and is a major player in the global market. Fukuda Denshi Co Ltd has a return on equity of 9.95%, which is relatively high for a large company. The company’s strong financial performance is due in part to its efficient operations and sound management.
– PetVivo Holdings Inc ($NASDAQ:PETV)
PetVivo Holdings Inc is a pet health and wellness company that focuses on the development and commercialization of pet health products. The company has a market capitalization of $25.78 million and a return on equity of -79.79%. The company’s products include a line of CBD-based pet health products, as well as a line of pet supplements.
Summary
Investor sentiment remains cautiously optimistic for LivaNova PLC, with the majority of analyst ratings placing the stock within the “Hold” range. Recent reports from five different ratings firms suggest that investors should remain open to the possibility of moderate returns but exercise a degree of caution in their approach. The stock is currently trading within the industry average price-to-earnings ratio, while its debt-to-equity ratio is slightly higher than its peers. Investors should also consider the wider market conditions when evaluating the stock’s future prospects.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
